STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype
Reported by STAT News · all stories from statnews.com
Editorial digest
Recent clinical disappointments for cardiovascular therapeutics suggest observers should temper optimism surrounding machine learning in drug discovery. The piece examines how clinical setbacks challenge broader enthusiasm about algorithm-driven pharmaceutical research.
Digests are written in our own words from the publisher's headline — we never reproduce article text. Read the original for the full reporting.
Read the full story at STAT News →More like this
Other stories our editors tagged with the same themes.
- Trusted health newsroom10/20/2026
STAT+: OpenEvidence’s JAMA paper leaves open questions
A recent journal publication regarding OpenEvidence still leaves several unanswered questions in medical technology.
- Trusted health newsroom10/13/2026
STAT+: Takeaways from an evaluation of Google’s diagnostic chatbot, AMIE
An assessment of Google's diagnostic AI chatbot, AMIE, has provided key findings.
- Trusted health newsroom9/11/2026
STAT+: An AI tool aims to catch harder-to-detect heart attacks in EKGs
An artificial intelligence solution helps detect subtle heart attacks using EKG scans.
- Trusted health newsroom9/30/2026
STAT+: HHS announces new efforts to speed up, expand clinical trials with AI
HHS initiatives aim to accelerate and broaden clinical research with artificial intelligence.
- Trusted health newsroom9/29/2026
STAT+: Anthropic joins ARPA-H clinical AI moonshot, will hold closed-door health care event
Anthropic will participate in ARPA-H's clinical AI initiative and host a healthcare event.
- Trusted health newsroom9/10/2026
STAT+: Can AI save rural health care?
The potential role of artificial intelligence in supporting rural healthcare is being explored.